# INM-901 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/inm-901

> The next catalyst for INM-901, sponsored by InMed Pharmaceuticals Inc. (MTRI), is its trial start, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for INM-901?

The next catalyst for INM-901, sponsored by InMed Pharmaceuticals Inc. (MTRI), is its trial start, 2027. Press release filed with the SEC (EX-99): ""Looking ahead in 2026, our primary focus is executing activities toward a pre-IND meeting with the FDA in Q3 to discuss the INM-901 program, which we believe will be a key inflection point as we work toward IND submission and initiation of a Phase 1 clinical trial in 2027." [Calendar and source filings](https://sec-api.dev/pdufa/inm-901)

Source: Press release filed with the SEC (EX-99), accession 0001062993-26-001347, https://www.sec.gov/Archives/edgar/data/1728328/000106299326001347/exhibit99-1.htm (retrieved 2026-11-12). Last confirmed 2026-03-09. Cite: https://sec-api.dev/pdufa/inm-901#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | INM-901 |
| Codes | INM-901 |
| Sponsor | InMed Pharmaceuticals Inc. (MTRI) https://sec-api.dev/companies/mtri/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 30, 2024: interim data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2024-11-14, last confirmed 2024-11-14.
- SEC Form 10-Q (accession 0001213900-24-098445): "July 30, 2024 — we announced positive results from initial data sets from a long-term (7 months of dosing) in vivo preclinical Alzheimer's Disease ("AD") study of" https://www.sec.gov/Archives/edgar/data/1728328/000121390024098445/ea0219774-10q_inmed.htm

### 2027: trial start

- Status: scheduled. Date confidence: year. Stage: 1.
- First seen 2026-03-09, last confirmed 2026-03-09.
- Press release filed with the SEC (EX-99) (accession 0001062993-26-001347): ""Looking ahead in 2026, our primary focus is executing activities toward a pre-IND meeting with the FDA in Q3 to discuss the INM-901 program, which we believe will be a key inflection point as we work toward IND submission and initiation of a Phase 1 clinical trial in 2027." https://www.sec.gov/Archives/edgar/data/1728328/000106299326001347/exhibit99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/inm-901.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "INM-901 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/inm-901

```bibtex
@misc{secapidev_pdufa_inm_901_20261116,
  title        = {INM-901 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/inm-901}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_inm_901_20261116","title":"INM-901 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/inm-901","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
